Kornimate/medical-research-clean huggingface dataset:
feasibility of prostatic arterial embolization in low-risk patients with unilateral prostate cancer under active surveillance: monocentric pilot study

Conditions: Prostate Cancer

Summary: the authors hypothesize that, in patients with low volume tumors identified according to anatomo-pathological criteria and imaging, and under active surveillance focal, therapy by unilateral embolization of prostatic arteries will provide local control of the tumor via selective ischemia


Eligibility criteria:
inclusion criteria: * the patient must have given their free and informed consent and signed the consent form * the patient must be a member or beneficiary of a health insurance plan * the patient is between 18 and 80 years old * patient has unilateral prostate cancer, stage tnm\<t2b with an mri pirads target ≥ 3 in concordance with biopsy result * biopsy gives a gleason score ≤ 6 with more than 3 positive biopsies per lob and at least 50% the length of the positive biopsy; patients over 70 years old with a gleason score = 7 (3+4) can be included * patient has a life expectancy of over 10 years * psa \<10ng/ml; patients with a large prostatic volume and psa ≥ 10ng/ml can be included according to doctor discretion. exclusion criteria: * the subject is participating in an interventional study, or is in a period of exclusion determined by a previous study * the subject refuses to sign the consent * it is impossible to give the subject informed information * the patient is under safeguard of justice or state guardianship * patient unresponsive to active surveillance * patient refusing active surveillance * patients in a state unfit to express personal consent cannot be solicited (eg patients undergoing psychiatric treatment with mental difficulties rendering consent impossible) * contraindication for mri (pacemaker incompatible with mri, claustrophobia, metal device, prosthetic hip replacement) * patient with hemostasis disorder. * cancer in both prostate lobes
study of brain response to emotional pictures using a magnetic resonance imaging (fmri) while on escitalopram

Conditions: Major Depression

Summary: the purpose of this study is to find out what parts of the brain have increased or decreased activity when people are depressed and how antidepressant medicine changes this activity in depressed patients. the genetic samples collected are to look at variation in a gene (serotonin transporter gene), which affects the functioning of the chemical serotonin in the brain

this study will measure the activity in different parts of the brain, while the patients are seeing some pictures, using magnetic resonance imaging (mri) scan. for this study three mri scans will be conducted. one before the patient begins on any medication, one during the study after 3 weeks of treatment and one after six more weeks of treatment with a standard antidepressant called escitalopram(trade name: lexapro).

Eligibility criteria:
inclusion criteria: * ages 18-50 years and able to give voluntary informed consent. * satisfy criteria for major depressive disorder (mdd) and current depressed episode using the mini international neuropsychiatric interview (m.i.n.i.). * 17-item hamilton depression rating scale (hdrs) score \> 18. * satisfy criteria to undergo an mri scan based on mri screening questionnaire. * able to be managed as outpatients for initial assessment and during treatment as ascertained by the following - * symptoms not worsening by more than 10 points on the hdrs during the course of the study. * no danger to self or others. exclusion criteria: * meeting dsm-iv criteria for schizophrenia, schizophreniform disorder, schizoaffective disorder, bipolar disorder, atypical psychosis, mental retardation, or organic mental (including organic mood) disorder. * on monoamine oxidase inhibitors in the past 2 weeks. * history of narrow angle glaucoma. * lack of response of the current episode of depression to two or more adequate courses of antidepressant therapy at a clinically appropriate dose for a minimum of 4 weeks or, in the judgment of the investigator, the patient meets criteria for treatment-resistant depression. * use of neuroleptic in the past 2 weeks. * use of antidepressants in the past 2 weeks. if on fluoxetine in the past, then should not have been on this medication for 4 weeks. * use of mood stabilizers in the past 2 weeks. * use of benzodiazepines in the past 2 weeks. * acutely suicidal or homicidal or requiring inpatient treatment. * meeting dsm-iv criteria for other substance dependence within the past year, except caffeine or nicotine. the criteria will be evaluated by interview and urinary toxicology screening initially and on test days. * use of alcohol in the past 1 week. * no serious medical or neurological illness as assessed by physical examination and laboratory examination including cbc and blood chemistry. * current pregnancy or breast-feeding. * metallic implants. * previously known positive hiv blood test as reported by the subject.

Keywords: escitalopram lexapro fmri pictures
effects of mindfulness training on burnout and mood in hospital employees

Conditions: Anxiety Depression; Burnout

Summary: the primary aims of the study are to 1) provide a hospital employee population with a mindfulness based stress reduction workshop and 2) evaluate the impact of this clinically validated group mindfulness intervention on burnout in health care employees. secondary outcomes will be anxiety, depression, quality of life and self compassion.


Eligibility criteria:
inclusion criteria: * english speaking * employees of stanford health care * ability to attend a minimum of 4 out of 6 sessions exclusion criteria: * non-english speaking * employees with severe medical or psychiatric conditions that prevent them from participating in the group format

Keywords: self-compassion meditation health personnel
adipose-derived stem cell conditioned media as a novel approach for hair regrowth in male androgenetic alopecia

Conditions: Alopecia, Androgenetic; Hair Loss/Baldness

Summary: this study investigated the efficacy of adipose derived stem cell conditioned media (adsc-cm) combined with minoxidil for hair regeneration therapy in male aga.

this study was a double-blind, randomized clinical trial (rct). two concentrations of adsc-cm were utilized: concentrated and non-concentrated adsc-cm. the scalp was divided vertically in half; one side was injected with 2 ml of adsc-cm, while the control side received 2 ml of nacl 0,9%. after the injection, patients applied topical 5% minoxidil twice daily. clinical improvements were assessed using photographic evaluation and trichoscan every two weeks.

Eligibility criteria:
inclusion criteria: * males aged 25-58 years old * hamilton-norwood criteria grades ii to vi * cessation of anti-androgens and minoxidil treatment for at least one month exclusion criteria: * patients with hair loss other than aga, such as alopecia areata, chemotherapy-induced alopecia, autoimmune-induced alopecia, and scalp malignancies; * patients receiving 5-alpha reductase inhibitor therapy; * patients who had received growth factor treatment (platelet-rich plasma or microneedling) for at least six months prior to the study; and * history of hypertrophic scars or blood clotting disorders.

Keywords: stem cell therapy adipose derived stem cell conditioned media hair regeneration
effect of tramadol in prevention of postpartum depression

Conditions: Caesarean Section

Summary: the incidence of postpartum depression in europe and the united states is about 10%, while in china the incidence rate of 15.7-39.8%. postpartum depression is one of the most common diseases of perinatal distress, but the current research of high-quality prevention and treatment of postpartum depression is still very lack. the study suggests that the risk of postpartum depression in cesarean delivery is significantly higher than that in vaginal delivery. therefore, postpartum depression in cesarean delivery may require more attention and treatment.tramadol is a non-opioid central analgesic that relieves common to severe pain, and tramadol has an inhibitory effect on norepinephrine and serotonin systems and has the potential to reduce depression and anxiety. therefore, for the analgesic demand and antidepressant demand for maternal who undergoing cesarean section, tramadol may be an optimized and effective analgesic for the prevention and treatment of postpartum depression.

this study was designed according to a prospective, randomized, controlled clinical trial. randomized subjects were randomly assigned to different analgesic drug-treated groups according to the random number induced by spss software. all three analgesic treatments were routinely used for clinical analgesia; anesthesia, surgery, postoperative treatment are in accordance with clinical practice. the investigators conducted a postoperative questionnaire survey and psychological diagnosis for all patients. and blood sample was collected from patients before and 48 hours after the surgery.

Eligibility criteria:
inclusion criteria: * 20 years old ≤ age ≤ 40 years old; * asa score i-ⅱ; * uncomplicated and singleton full-term pregnancy; * voluntarily to receive cesarean section and postoperative controlled analgesia; * consent to participate the study. exclusion criteria: * with history of mental disorders or psychotropic substances use; * with history of neurological diseases such as epilepsy * with history of previously known diagnosed depression; * with suicidal ideation or history of suicide; * with history of drug，alcohol or opioid abuse; * with monoamine oxidase (mao) inhibitor treatment at present or in the past 14 days; * participating in other clinical studies * with severe heart disease, brain disease, liver disease and kidney disease; * be allergic to tramadol or opioids; * with any contraindication for combined spinal epidural anesthesia; * incapable of communication or cooperation.
efficacy of topclosure(c)system in healing complicated pacemaker wounds

Conditions: Wounds and Injuries

Summary: patients receiving oral anticoagulation or anti-platelet therapy are at high risk of hematoma after device implantation. this study intends to examine the efficacy of the topclosure(c) system in wound healing in these patients.


Eligibility criteria:
inclusion criteria: * patients treated with anticoagulant therapy * patients treated with antiplatelet therapy exclusion criteria: * none
self-management and resourceful transition of type 2 diabetes with stage 3 kidney disease

Conditions: Diabetes Mellitus, Type 2; Renal Insufficiency, Chronic

Summary: the purpose of this study is to establish the usefulness and the impact of a tailored behavioral-education and counseling intervention titled self-management and resourceful transition (s.m.a.r.t) among patients with type 2 diabetes mellitus and stage 3 chronic kidney disease, in order to help them to manage their behaviors related to their condition and health.

the smart intervention is a 3-week intervention that uses a combined behavioral-education and counseling methodology. the combined intervention involves computer-aided education alongside telephone counseling via motivational interviewing. the computer-aided education is tailored to the diagnoses of type 2 diabetes and chronic kidney disease and designed in a learning module approach to facilitate goal-setting and discussion of health concerns with greater efficacy and in a more informed way during the brief office visit. such computer-aided education has been used to improve diabetes self-management and glycemic control in middle-aged to older adults with moderate success. the inclusion of ckd information will augment current diabetes self-management intervention. the telephone counseling using the evidence-based behavioral change approach of motivational interviewing is a patient-centered approach of partnering with patients by eliciting their health-related concerns. this approach tailors the smart intervention to include collaborative goal-setting with guidance based upon the patient's readiness for change.

Eligibility criteria:
inclusion criteria: * diagnosed type 2 diabetes * 18-85 years old * stage 3 chronic kidney disease * speaks and reads english exclusion criteria: * hypoglycemia with 3rd party treatment in past 3 months * type 1 diabetes * on dialysis * does not speak english * factors likely to preclude protocol adherence

Keywords: self-care self-management health behavior change motivational interviewing computer assisted learning
intra uterine growth restriction

Conditions: Intrauterine Growth Restriction

Summary: intrauterine growth restriction (iugr) is associated with an increase in perinatal mortality and morbidity, as well as longer-term neurological, cognitive, cardiovascular and endocrine complications. in europe, about 400,000 pregnancies per year are complicated by iugr. however, antenatal diagnosis seems insufficient in clinical practice, making it impossible to recognize up to 75% of foetuses with iugr. at a time when the use of good clinical practice has demonstrated a significant improvement in neonatal survival without severe morbidity, foetuses with iugr are less likely to receive optimal care. our hypothesis is that the rate of iugr diagnosed underestimates the rate of actual iugr.


Eligibility criteria:
inclusion criteria: * all birth more than 24 + 0 weeks of amenorrhea at the maternity ward of the hospital femme-mère-enfant * from 1st of january 2011 to 31 december 2017. exclusion criteria: * infants born out of the hospital and secondarily hospitalized in the hospital femme-mère-enfant . * multiple pregnancies, * children with congenital fetal anomalies * pregnancies without first trimester ultrasound (to date the pregnancy)
intervention to improve hiv care retention by addressing stigma stigmatized environments

Conditions: HIV I Infection

Summary: retention in care and persistent adherence to antiretroviral therapy are necessary for the successful treatment of hiv infection. hiv-related stigma is a known impediment to the care and health outcomes of people living with hiv. the proposed study will test theory-based interventions designed to manage hiv stigma in order to improve care retention and medication adherence in communities with high-levels of hiv-related stigma.

this trial is conducting a randomized test of a behavioral self-management intervention designed to improve hiv treatment outcomes in people living with hiv in stigmatized contexts. the trial includes a control arm and a non-stigma enhanced treatment adherence intervention arm. participants living in an economically under-resourced area of south africa are recruited through clinical care settings. the goal of the research is to examine whether directly addressing hiv stigma and medication adherence management improves treatment outcomes beyond those observed from a standard behavioral intervention without added stigma-addressing components.

Eligibility criteria:
inclusion criteria: 1. 18 years of age or older 2. current clinic visit to receive cart in differentiated care outside of an adherence club 3. unsuppressed hiv at the most recent clinical testing confirmed in run-in 4. access to a phone exclusion criteria: not meeting inclusion

Keywords: hiv
early detection of neuropathy and cognitive impairment following treatment for haematological malignancies

Conditions: Chemotherapy-induced Peripheral Neuropathy

Summary: chemotherapy-induced peripheral neuropathy (cipn) is a common, but not well understood complication to treatment with chemotherapy. in this study the investigators will investigate a novel method for early detection of cipn and compare it to other methods in patients treated for haematological cancers.

haematological malignancies can be treated with chemotherapy if the patient tolerates the treatment. however, many patients develop complications during treatment including chemotherapy-induced peripheral neuropathy (cipn) and/or impaired memory. even though it is a well-known complication, no gold standard for cipn assessment is known. besides chemotherapy reduction or cessation, there is so far no sufficient prevention or treatment, therefore early detection and intervention is crucial. the main purpose of this study is to find a reliable test for chemotherapy-induced peripheral neuropathy (cipn) in order to predict early signs of cipn. all included patients has to be scheduled for treatment with vincristine, bortezomib or lenalidomide regardless of haematological malignancy. neuropathy and cognitive impairment will be tested at baseline (prior to treatment with chemotherapy), before each treatment course, 1 month after treatment and finally 1 year after onset of chemotherapy. cipn will be examined by different methods: clinician-based assessment, objective neurophysiological parameters and patient-reported outcome. a novel test using perception threshold tracking (ptt), developed at aalborg university, is included in the study. the test investigates the nerve excitability in both large and small fiber nerve fibers using two different electrodes. blood samples will be collected, stored, and analyzed for deficiencies correlated to neuropathy.

Eligibility criteria:
inclusion criteria: * men and women, age ≥ 18 years * scheduled for treatment with vincristine (r-chop, chop, r-choep, choep, r-cvp, cvp or simi-lar), bortezomib (vcd, mpv, vrd or similar) or lenalidomide (vrd, len-dex or similar) regardless of type of haematological malignancy * not started chemotherapy treatment before enrollment (pretreatment with steroids is allowed) * associated to department of haematology, aalborg university hospital during the project period * signed informed consent form * able to read and speak danish exclusion criteria: * known vitamin b12 deficiency and treated with either oral or intramuscular vitamin b12 within the last year * known neural damage or disease in the neural system (e.g. ms, guillain-barre etc.) * known severe skin disease * pregnancy or breastfeeding * inability to understand or comply with instructions

Keywords: vincristine bortezomib lenalidomide assessment of nerve fiber excitability
safety, tolerability, and pharmacokinetics of fidaxomicin in pediatric subjects with clostridium difficile-associated diarrhea (cdad)

Conditions: Clostridium Difficile-associated Diarrhea

Summary: the purpose of this study is to determine the safety, tolerability, and pharmacokinetics of fidaxomicin in pediatric subjects with clostridium difficile-associated diarrhea (cdad).


Eligibility criteria:
inclusion criteria: * male or female 6 months to 17 years 11 months of age, inclusive; * female subjects of childbearing potential must use adequate contraception * diagnosed with cdad exclusion criteria: * concurrent use of oral vancomycin or metronidazole or any other effective treatments for cdad * fulminant colitis * history of inflammatory bowel disease * pregnant or breast-feeding * need for concurrent use of some p-glycoprotein inhibitors during therapy

Keywords: clostridium difficile-associated diarrhea cdad pediatric
optimal time for follow up after variceal band ligation

Conditions: Esophageal Varices

Summary: optimal time for follow up after variceal band ligation in cirrhotic patients remains to be determined

optimal time for follow up after variceal band ligation in cirrhotic patients remains to be determined. so, we designed this trial to answer this question.

Eligibility criteria:
inclusion criteria: * cirrhotic portal hypertension with medium or large sized or risky varices or variceal bleeding exclusion criteria: * non-cirrhotic portal hypertension
flowtriever2 pulmonary embolectomy clinical study

Conditions: Pulmonary Embolism

Summary: the flare-ft2 confirmatory study is a prospective, single-arm, multicenter study of the flowtriever2 catheter.


Eligibility criteria:
inclusion criteria: * clinical signs and symptoms consistent with acute pe * pe symptom duration ≤ 14 days * cta evidence of proximal pe (filling defect in at least one main or lobar pulmonary artery) * rv/lv ratio of ≥ 0.9 (note: enrollment qualification assessment based on investigator's interpretation of rv/lv ratio) * systolic blood pressure ≥ 90 mmhg (initial sbp may be ≥ 80 mmhg if the pressure recovers to ≥ 90 mmhg with fluids) * stable heart rate \< 130 bpm prior to procedure * patient is deemed medically eligible for interventional procedure(s), per institutional guidelines and/or clinical judgment. * flowtriever2 catheter enters the vasculature exclusion criteria: * thrombolytic use within 30 days of baseline cta * pulmonary hypertension with peak pulmonary artery pressure \> 70 mmhg by right heart catheterization * vasopressor requirement after fluids to keep pressure ≥ 90 mmhg * fio2 requirement \> 40% or \> 6 lpm to keep oxygen saturation \> 90% * hematocrit \< 28% (note: hematocrit required within 6 hours of index procedure) * platelets \< 100,000/μl * serum creatinine \> 1.8 mg/dl * inr \> 3 * major trauma injury severity score (iss) \> 15 * presence of intracardiac lead in the right ventricle or right atrium placed within 6 months * cardiovascular or pulmonary surgery within last 7 days * actively progressing cancer * known bleeding diathesis or coagulation disorder * left bundle branch block * history of severe or chronic pulmonary arterial hypertension * history of chronic left heart disease with left ventricular ejection fraction ≤ 30% * history of uncompensated heart failure * history of underlying lung disease that is oxygen dependent * history of chest irradiation * history of heparin-induced thrombocytopenia (hit) any contraindication to systemic or therapeutic doses heparin or anticoagulants * known anaphylactic reaction to radiographic contrast agents that cannot be pretreated * imaging evidence or other evidence that suggests, in the opinion of the investigator, the subject is not appropriate for mechanical thrombectomy intervention (e.g., inability to navigate to target location, predominately chronic clot, or non-clot embolus) * life expectancy of \< 90 days, as determined by investigator * female who is pregnant or nursing * current participation in another investigational drug or device treatment study
postoperative bmi changes and functional outcomes in knee and hip arthroplasty

Conditions: Arthropathy; Obesity

Summary: purpose obesity poses challenges to preoperative mobility and functional recovery for arthroplasty patients, yet postoperative weight loss remains elusive. this study aims to investigate postoperative weight changes and their impact on functional scores following knee and hip arthroplasty, exploring factors influencing these changes. methods a total of 459 knee and hip arthroplasty cases with a 2-year follow-up were analyzed. bmi and oxford scores were tracked, alongside factors including comorbidities, corticosteroid use, physiotherapy, and unilateral vs. bilateral surgery. expected outcomes based on the study's design and the data available, we anticipate observing the impact of changes in patients' bmi on clinical scores as an independent variable. additionally, we aim to elucidate the effects of comorbidities, corticosteroid use, physiatrist follow-up, and the type of surgical procedure on both bmi and clinical outcomes. through this analysis, we expect to gain a comprehensive understanding of how these factors interplay to influence postoperative recovery and overall patient health.


Eligibility criteria:
inclusion criteria: * patients who underwent primary tka and tha with a 2-year follow-up were included exclusion criteria: * patients who underwent bariatric surgery before or after the surgery * incomplete 2-year follow-up * whom bmi or oxford scores could not be accessed

Keywords: total hip arthroplasty total knee arthroplasty weight loss obesity body mass index